Related Experiment Video

Updated: Mar 8, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

3.2K

DNA methyltransferase inhibition is a therapeutic vulnerability in VHL-deficient renal cell carcinoma cells

Yue Pu1, Ziruoyu Wang2, Shishi Tao1,3

  • 1Cancer Centre, Faculty of Health Sciences, University of Macau, Taipa, China.

Experimental & Molecular Medicine
|March 6, 2026
PubMed

Insights

von Hippel-Lindau (VHL) deficiency in renal cell carcinoma (RCC) creates a vulnerability to DNA methyltransferase (DNMT) inhibitors. Restoring KCNK3 expression via DNMT inhibition triggers cell death, offering a targeted therapy approach.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • von Hippel-Lindau (VHL) is a tumor suppressor gene frequently inactivated in renal cell carcinoma (RCC).
  • VHL loss is linked to abnormal DNA methylation patterns in RCC.
  • VHL-deficient RCC cells exhibit unique vulnerabilities related to epigenetic regulation.

Purpose of the Study:

  • To investigate the therapeutic potential of DNA methyltransferase (DNMT) inhibitors in VHL-deficient RCC.
  • To elucidate the molecular mechanisms underlying the sensitivity of VHL-deficient RCC to DNMT inhibitors.
  • To identify novel therapeutic targets and strategies for personalized treatment of VHL-deficient RCC.

Main Methods:

  • Utilized a panel of VHL-deficient RCC cell lines and patient-derived xenografts.
  • Administered FDA-approved and investigational DNMT inhibitors (decitabine, azacitidine, RX-3117, SGI-1027).
  • Performed transcriptomic profiling, RNA interference screens, and mechanistic studies involving KCNK3, HIF-2α, TNF-α, and MAPK signaling.

Main Results:

  • VHL-deficient RCC cells showed selective sensitivity to DNMT inhibitors, leading to suppressed growth.
  • VHL loss upregulates DNMT1 via HIF-2α, causing widespread CpG hypermethylation.
  • DNMT inhibitors restored KCNK3 expression by reversing promoter hypermethylation, inducing synthetic lethality.
  • KCNK3 reactivation activated TNF-α, MAPK, and apoptotic pathways, mediating antitumor effects.

Conclusions:

  • DNA methyltransferase inhibition represents a synthetic lethal strategy for VHL-deficient RCC.
  • KCNK3 is a critical mediator of DNMT inhibitor-induced synthetic lethality in this context.
  • Targeting DNMTs offers a promising avenue for personalized therapeutic approaches in VHL-deficient RCC.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K
Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

9.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
51
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K